Russia completes first time ever localization of an orphan drug, including biosynthesis of its drug substance
Petrovax Pharm reports to have completed authorization procedures for the drug Fabagal® (agalsidase beta) manufactured locally (full-cycle production) and used to treat Fabry disease[1]. This is the first orphan drug in Russia to have its drug substance synthesis technology transferred in the country. The project has been implemented in cooperation with the N.F. Gamaleya NCEM.
Experts: Adding Fabry disease to the list of high-cost nosologies is necessary to reduce patient mortality
Mysteries of Fabry Disease Discussed at Forum in Tashkent
Family screening as a key to identifying Fabry disease patients
